Study type

Study topic

Human medicinal product
Disease /health condition

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Drug utilisation

Data collection methods

Combined primary data collection and secondary use of data
Non-interventional study

Non-interventional study design

Cross-sectional
Other

Non-interventional study design, other

Retrospective study
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(L04AC13) ixekizumab
ixekizumab
(L04AC13) ixekizumab
ixekizumab
(L04AC10) secukinumab
secukinumab
(L04AA32) apremilast
apremilast
(L04AB04) adalimumab
adalimumab
(L04AC16) guselkumab
guselkumab

Medical condition to be studied

Psoriasis
Population studied

Short description of the study population

Psoriasis patients under treatment in our Hospital during the last year. Inclusion criteria were psoriasis being under biologics or small molecules during the onset and the development of the crisis, verbal consent and adulthood. Exclusion criteria included impossibility of telephone contact or refusal to participate.

Age groups

  • Adult and elderly population (≥18 years)
    • Adults (18 to < 65 years)
      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)
      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Special population of interest

Immunocompromised

Estimated number of subjects

174
Study design details

Main study objective

We sought to clarify the status of patients on immunosuppressive or immunomodulator drugs with respect to possible COVID-19 involvement and to detect changes in their treatment regimen, the reason why they made them as well as the influence in their social behaviour.

Data analysis plan

A statistical analysis was performed with chi-squared, Fisher exact tests and Student’s t-test using Statistical Package for Social Sciences (SPSS®) for Windows, version 25.0 (Armonk, NY: IBM Corp).